Advertisement

Topics

Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections

03:15 EDT 12 Aug 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Basilea Pharmaceutica AG / Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the con...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...